TNFRSF1A and acute respiratory distress syndrome: Based on this mechanism of action, the inhalation of GSK 1995057, a selective TNFR1 antagonist, is considered a possible therapeutic approach for preventing ARDS.309 A randomized controlled clinical trial involving 37 healthy individuals showed that the inhalation of GSK-1995057 can prevent the increase in neutrophil counts, inflammatory cytokine levels, and endothelial cell injury observed in healthy individuals exposed to inhaled endotoxin.310